Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris and Hikma Pharmaceuticals have entered an exclusive commercialization and licensing agreement to market Aeterna Zentaris' anti-cancer compound, perifosine for the MENA (Middle East and North Africa) region.
Subscribe to our email newsletter
Perifosine is an oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
The drug is in two Phase 3 programs for the treatment of colorectal cancer and multiple myeloma.
As per the licensing agreement, Aeterna Zentaris will receive an upfront payment and additional payments upon achieving certain pre-established milestones in the aggregate of $2m.
Aeterna Zentaris will also supply perifosine to Hikma Pharmaceuticals on a cost-plus-basis and receive royalties on future net sales of perifosine in the MENA region.
Hikma Pharmaceuticals will take up the charge of registration and commercialization of the drug in the MENA territory.